Anemia, Oncologic Complications
Conditions
Keywords
Transfusion, Pilot study, critically ill patients, oncologic surgery
Brief summary
Anemia is common in oncology. Up to three-quarters of cancer patients are exposed to an episode of anemia. In oncology surgery, perioperative bleeding is a major risk factor for anemia. Indeed, 13 to 40% of patients are transfused in perioperative oncologic surgery. There is an association between anemia and prognosis. Several epidemiological studies have shown a strong association between anemia and altered quality of life. In oncology cohort studies, anemic patients had a significantly lower quality of life compared to patients without anemia. In non-cardiac surgery, preoperative anaemia was significantly associated with post-operative mortality. There is also an association between preoperative anaemia and the occurrence of post-operative complications. In oncology surgery, cohort studies conducted in colorectal surgery and neurosurgery found an association between the occurrence of perioperative anemia and post-operative morbidity and mortality. The optimal transfusion strategy is unknown in oncology patients. Several multicentre randomised trials, conducted in resuscitation patients or in perioperative settings, have compared a restrictive to a liberal transfusion strategy. These studies did not show a superiority of one strategy over another on patient outcomes but a lower exposure to red blood cell concentrates in patients transfused with the restrictive transfusion strategy. Thus, the French High Authority for Health (HAS) has adopted a haemoglobin level of 7 g/dl as the transfusion threshold for any transfusion of red blood cell concentrate carried out in the operating theatre and in intensive care in the absence of special cases such as the presence of acute coronary syndrome. For oncology patients, no recommendation could be made due to the lack of evidence-based literature and the optimal transfusion strategy for these patients remains unknown. Only 2 monocentric trials performed in oncology (critical care and perioperative) suggest a benefit of a liberal strategy (transfusion for a haemoglobin level \< 9 g/dl) on the short-term vital prognosis, but these studies suffer from numerous limitations leaving the question unresolved. Before conducting a large phase III trial, a pilot study is needed to validate the methodology of this multicentre clinical trial and to assess its feasibility.
Interventions
OTHERHaemoglobin 9.5 g/dL
transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
OTHERHaemoglobine 7.5g/dL
transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL
Sponsors
University Hospital, Brest
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Pilot, multicentre, randomized, controlled, single-blind, pilot study comparing two strategies for transfusion of red blood cell concentrates
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years old * Anticipated or proven admission to immediate postoperative resuscitation after scheduled or emergency oncology surgery, for the removal of a neoplastic lesion among the following surgical procedures: * Visceral surgery: Hepatectomy, duodenopancreatectomy, gastrectomy, esophagectomy, colectomy * Urological surgery: Radical prostatectomy, cystectomy, nephrectomy. * Gynaecological surgery: Ovariectomy, hysterectomy, mastectomy, pelvectomy * Thoracic surgery: Pneumonectomy, lobectomy * ENT Surgery: Total laryngectomy, pharyngectomy, glossectomy * Spinal surgery: corporectomy wherever it is performed. * Hemoglobin level \< 9.5 g/dl between the day before surgery (D-1) and discharge from resuscitation at no more than 30 days postoperatively
Exclusion criteria
* \- Myocardial infarction and/or unstable angina in the 4 weeks prior to surgery * Refusal to participate in the study * Minor patient (age \< 18 years) * Refusal to transfuse red blood cell concentrates (Jehovah's Witness) * Pregnant or breastfeeding women * Patients under guardianship or curatorship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Methodology of the pilot study | up to 30 days | The difference in mean hemoglobin levels during the perioperative period up to 30 days postoperatively between the two groups will be assessed |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Epidemiological data of the pilot study | up to 90 days | The percentage of patients with oncologic surgery admitted to intensive care unit requiring transfusion of red blood cell concentrates eerioperatively among aatients with oncologic surgery admitted to intensive care unit will be assessed |
| Adverse Reaction Monitoring | up to 30 days | To compare the occurrence of transfusion-related adverse events in each group |
| Evaluation of the functional status | up to 30 days | Test functional status assessment at 30 days postoperatively using the World Health Organization Disability Assessment Schedule (WHODAS) questionnaire. This questionnaire asks about difficulties due to health/mental health conditions. Health conditions include diseases or illnesses, other health problems that may be short or long lasting, injuries, mental or emotional problems, and problems with alcohol or drugs. The patient must think back over the past 30 days and answer the questions thinking about how much difficulty you had doing the following activities. |
| Evaluation of the functional status after surgery ans anesthesia | up to 30 days | Test functional status assessment at 30 days postoperatively using the Quality of recovery questionnaire. The Quality of Recovery-15 (QoR-15) is a psychometrically tested and validated questionnaire. The QoR-15 was psychometrically evaluated using data collected from patients who responded at all four time intervals.This included: Acceptability and Feasibility; Validity; Reliability; Responsiveness |
| Monitoring of the quality of the study's execution | up to 30 days | Compare the percentage of protocol violations in the 2 groups |
Countries
France
Outcome results
None listed